GlassScriptPhysician profile
Lauren S Gray
NPI 1740798164
$1,181.49
in general payments reported to CMS, 2019-2025
20 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $86.98 · 2023: $349 · 2024: $230 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $760.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $272.70 | 2021-2024 | |
| Novo Nordisk INC | $271.44 | 2021-2025 | Rybelsus, Ozempic |
| Beigene USA, INC. | $150.00 | 2023 | Brukinsa |
| Lilly USA, LLC | $59.71 | 2023-2025 | Mounjaro |
| Amgen INC. | $44.86 | 2025 | Otezla, Repatha |
| Janssen Biotech, INC. | $43.57 | 2024 | Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $40.07 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.39 | 2025 | Caplyta |
| Pharmacosmos Therapeutics INC. | $32.13 | 2024 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $31.46 | 2024 | Airsupra |
| Progenics Pharmaceuticals, INC. | $30.85 | 2023 | Pylarify |
| Supernus Pharmaceuticals, INC. | $30.62 | 2025 | Qelbree |
| Pfizer INC. | $26.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.17 | 2023 | Alunbrig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.10 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $18.37 | 2025 | Ibsrela |
| Exact Sciences Corporation | $13.88 | 2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $13.73 | 2022 | |
| Dexcom, INC. | $13.50 | 2021 | |
| Amarin Pharma, INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.